Genentech: Kate Peng | Senior Scientist, BioAnalytical Sciences, Assay Development and Technology, Department of Development Sciences

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/kate-peng

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"Genentech is a unique place. It has been extremely rewarding for me to work in a cross-functional environment with incredibly dedicated and talented colleagues to identify solutions for unmet medical needs."

Years at Genentech

Publications

Awards & Honors

I joined the BioAnalytical Research & Development department at Genentech in 2007 after working in the biotech industry for three years. I am currently a Senior Scientist in the Assay Development and Technology group within the BioAnalytical Sciences department. During my time at Genentech, I have gained experience and expertise in developing bioanalytical strategies and methods to enable appropriate assessment of the pharmacokinetics, immunogenicity and pharmacodynamics of protein biotherapeutics, interact with health authorities as well as retain knowledge of both nonclinical and clinical drug development.

Featured Publication

Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.

MAbs. 2014;6(6):1500-8.

Peng K. Xu K, Liu L, Hendricks R, Delarosa R, Erickson R, Budha NR, Leabman M, Song A, Kaur S, Fischer SK.

View Abstract

Develop bioanalytical strategies, methods and technologies enabling assessment of the pharmacokinetics, pharmacodynamics and immunogenicity of protein biotherapeutics from early development to clinical as well as post-marketing studies, with a focus on immunological diseases. Support regulatory filings by drafting filing documentations (IND, CTA, BLA) and interacting with healthy authorities on bioanalytical related discussions.

Characterization of robust immune responses to a bispecific antibody, a novel class of antibody therapeutics

Bioanalysis, ISSN: 17576180

Kate Peng; Ketevan Siradze; Sally Fischer

A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)

Clinical and Experimental Allergy, ISSN: 09547894

Cary Austin; Melissa Gonzalez Edick; Ronald E. Ferrando; Margaret Solon; Miriam Baca; Kathryn Mesh; Peter Bradding; Gauvreau; Kaharu Sumino; FitzGerald; Elliot Israel; Lief Bjermer; Arnaud Bourdin; Joe Arron; David Choy; Julie Olsson; Francis Abreu; Monet Howard; Kit Wong; Fang Cai; Kun Peng; Wendy Putnam; Cecile Holweg; John Matthews; Monica Kraft; Prescott G. Woodruff

A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology

BMC Pulmonary Medicine, ISSN: 14712466

Tracy Staton; Kate Peng; Ryan Owen; David Choy; Christopher R. Cabanski; Alice Fong; Flavia Brunstein; Kathila R. Alatsis; Hubert Chen

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

A link to this page has been copied to your clipboard.

Kate Peng

Senior Scientist, BioAnalytical Sciences, Assay Development and Technology, Department of Development Sciences

Featured Publication

Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.